Login / Signup

Limited impact of Der p 23 IgE on treatment outcomes in tablet allergy immunotherapy phase III study.

Thomas StranzlHenrik IpsenLars Harder ChristensenThomas EiweggerNiels JohansenKaare LundPeter Sejer Andersen
Published in: Allergy (2020)
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • double blind
  • phase ii
  • randomized controlled trial
  • placebo controlled